AGM
STML

Alpine Global Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Alpine Global Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-20,000
Closed -$392K – 191
2013
Q4 		$392K Buy
+20,000
New +$534K 0.63% 37

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Alpine Global Management's STML Position: Q1 2014 in Review

Alpine Global Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2014, closing a stake of 20,000 shares — an estimated $392K sold.

Alpine Global Management first reported a position in STML in Q4 2013 and held it in 1 quarter. The position peaked at $392K in Q4 2013. 61 funds tracked by Wall St. Rank hold STML as of Q1 2014.

  • Alpine Global Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
  • Alpine Global Management sold 20,000 Stemline Therapeutics, Inc. shares in Q1 2014, an estimated $392K.
  • Alpine Global Management first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 1 quarter.
  • Alpine Global Management's Stemline Therapeutics, Inc. position peaked at $392K in Q4 2013.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2014.

Based on Alpine Global Management's 13F filing for Q1 2014, filed 15 May 2014.